Clinical trials: Spinal Infection
Pertussis, Diphtheria
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
Post-marketing evaluation of reactions following receipt of recommended adolescent pertussis vaccine among persons with prior vaccination with acellular vs whole-cell pertussis vaccine.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00304265
- Testing
- COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)
- Where
- 17 sites in Germany
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis
Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
The purpose of this clinical trial is to assess the safety and tolerability (primary objective), immunogenicity (primary and secondary objectives), fecal shedding of vaccine viruses (secondary objective) and the potential for…
- Trial name
- NCT05654467
- Testing
- Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3), Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3)
- Where
- 3 sites in Panama
- Volunteers
- 1,532 people, healthy volunteers welcome
- Sponsor
- PATH
Acellular Pertussis, Tetanus
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age
The purpose of this study is to show that the immunogenicity of newly formulated DTPa-HBV-IPV/Hib vaccine is as good as the immunogenicity of the currently licensed formulation of the vaccine.
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria, Hepatitis B
- Trial name
- NCT00376779
- Testing
- Infanrix hexa Vaccine
- Where
- 6 sites in Finland
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Polio
Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV
The goal of this clinical trial is to explore two strategies to enhance nOPV2 immunogenicity in the field and overcome potential interference of bOPV: 1.
- Trial name
- NCT06114810
- Testing
- polio vaccines: nOPV2, bOPV, IPV
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Polio
Polio NID and Routine EPI Integration Trial Pakistan
This study aims to assess if pictorial messages promoting routine immunization during supplementary campaigns for oral polio vaccine in areas with poor DTP3 vaccine coverage can improve immunization rates.
- Trial name
- NCT01697280
- Testing
- Vaccine promotion messages, Vaccination Verification., Distribution of Plastic Pouches to retain vaccination card
- Where
- Pakistan
- Volunteers
- 4,560 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Polio
Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally
Polio is an acute transmissible disease caused by any of the three polio virus serotypes (types 1, 2 or 3). In Mozambique, polio vaccination is part of the immunization schedule of the expanded vaccination program.
- Trial name
- NCT04027036
- Testing
- Inactivated poliovirus vaccine in reduced doses
- Where
- 2 sites in Mozambique
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Saúde, Mozambique
Poliomyelitis
Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines
The main objectives of this study are to : evaluate the safety and tolerability of trivalent novel oral poliovirus vaccines (tnOPV) in healthy adults, young children, and neonates, relative to those receiving control vaccines…
- Trial name
- NCT06137664
- Testing
- Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2), Novel oral poliomyelitis vaccine type 3 (nOPV3)
- Where
- 2 sites in Bangladesh
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- PATH
Poliovirus Vaccine, Inactivated, Poliomyelitis
Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan
This study will be conducted in four low-income areas of Bin Qasim Town Karachi. This will be a community based randomized control trial of 21 months duration.
- Conditions
- Poliovirus Vaccine, Inactivated, Poliomyelitis, Immunization; Infection
- Trial name
- CODI (NCT03286803)
- Testing
- Inactivated Poliovirus vaccine
- Where
- Pakistan
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Post-polio Syndrome
Activity and Fatigue of the Respiratory Muscles and Pulmonary Characteristics in Post-Polio Patients
Background: Early diagnosis of respiratory impairment in Post-Polio (PPS) patients may delay respiratory decline and future need of invasive respiratory aids.
- Trial name
- NCT03064711
- Testing
- Electronyugraphy
- Where
- Israel
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
to See Whether Negative Pressure Wound Therapy Decreases Wound Infections.
Negative Pressure Wound Therapy - A Multi-Centered Randomized Control Trial
Children with neuromuscular disorders such as cerebral palsy, children with kyphosis and post-traumatic scoliosis have higher infection rates after scoliosis surgery than healthy children who undergo scoliosis surgery.
- Trial name
- NPWT (NCT02790385)
- Testing
- Negative Pressure Wound Therapy, Standard Gauze Treatment
- Where
- Canada
- Volunteers
- 870 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Poliomyelitis
Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine
This is an open label and off label, phase IV, randomized clinical trial that will compare the immune response among infants that receive either two full doses of Sabin IPV intramuscularly or two fractional (1/5) dose of Sabin…
- Trial name
- NCT05460377
- Testing
- Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS, Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS, Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP
- Where
- Bangladesh
- Volunteers
- 1,224 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Immunity to Polio Vaccines in Malnourished Infants, Immunity to Polio Vaccines in Non-malnourished Infants
IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi.
Chronic malnutrition is associated with lack of effective gut immunity which is a possible explanation for why we see polio cases among a proportion of children who have received 7 or more doses of OPV.Our proposed idea is to…
- Trial name
- MIPV (NCT01695798)
- Testing
- Injectable polio vaccine and Bivalent oral polio vaccine
- Where
- Pakistan
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Poliomyelitis
Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months
The trial is a phase III, non-inferiority, observer-blind, randomised, controlled, multicentre clinical trial with 2 parallel groups: IPV-Al SSI (investigational vaccine) and IPV SSI (reference vaccine)
- Trial name
- VIPV-06 (NCT03032419)
- Testing
- IPV-Al SSI, IPV SSI
- Where
- Philippines
- Volunteers
- 1,002 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Diphtheria, Hepatitis B
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
The purpose of this study is to assess the immunogenicity and safety of the Infanrix hexa booster dose given at 11-18 months of age to infants who received primary vaccination at 6-14 weeks.
- Conditions
- Diphtheria, Hepatitis B, Acellular Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT02853929
- Testing
- Infanrix hexa
- Where
- 29 sites in Australia, Canada and 4 more
- Volunteers
- 551 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection
Analysis of the Incidence of Post-Operative Wound Infections After Spine Surgery
Post-operative wound infections can prolong hospital stays, increase rates of readmission to the intensive care unit, and increase the costs of treatment significantly.
- Trial name
- NCT02891486
- Testing
- Spinal surgery
- Where
- 2 sites in United States
- Volunteers
- 6,959 people, healthy volunteers welcome
- Sponsor
- University of Miami
Hepatitis B, Polio
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV
The purpose of this study is to document the immunological response to the investigational hexavalent vaccine at the 6, 10, and 14 weeks schedule The primary objective is to demonstrate that the hexavalent DTaP-IPV-HB-PRP~T…
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00362336
- Testing
- DTaP-IPV-HB-PRP~T, CombAct-HIB®, Engerix B® Pediatric
- Where
- 2 sites in South Africa
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China
The study will assess the safety of Pentaxim® vaccine as a three-dose primary vaccination at 2, 3, and 4 months of age in order to meet the regulatory requirements for the license renewal as for any other product registered in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- NCT01491087
- Testing
- DTacP IPV//PRP~T combined vaccine: PENTAXIM®
- Where
- 3 sites in China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis
Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine
This Phase III study has been designed to compare the SII Inactivated Salk Polio Vaccine (Adsorbed) with Sii licensed IPV by testing the vaccine in infants (three doses administered 4 weeks apart, starting at 6-8 weeks of age) in…
- Trial name
- NCT05163561
- Testing
- SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A, SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B, SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C
- Where
- Bangladesh
- Volunteers
- 1,072 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Poliomyelitis
Safety and Immunogenicity of IPOVAC in Young Children
A dose escalating study with 3 different dosing regimens of the studied vaccine (IPOVAC- POLYVAC-Vietnam) and a licensed vaccine (IMOVAC-Sanofi Pasteur- France) is conducted in Vietnamese children, aged 2 months and above to…
- Trial name
- NCT02775942
- Testing
- IMOVAC-POLIO, IPOVAC 1.5:5:5, IPOVAC, 3:10:10
- Where
- 2 sites in Vietnam
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Institute of Hygiene and Epidemiology, Vietnam
Poliomyelitis, Polio
Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan
The aim of the study is to assess the immunogenicity of SP059 (IMOVAX POLIO®: Inactive Poliovirus Vaccine) vaccine against poliovirus and safety after fifth dose.
- Trial name
- NCT02005536
- Testing
- IMOVAX POLIO®: Inactive Poliovirus Vaccine
- Where
- 4 sites in Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company